NCT06749301Completed
Repeatability and Reproducibility of the ADC Map in Head and Neck Cancer. Prospective Multicenter Study
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
Evaluation of the repeatability and reproducibility of ADC maps in both primary and non-primary lesions lymph nodes in patients with head and neck cancer, using an acquisition protocol Standardized DWI
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 58 (actual)
- First submitted
- 19 Dec 2024
- Start date
- 11 Sept 2023
- Primary completion date
- 11 Mar 2025
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Head and neck cancer
- NCT number
- NCT06749301
What you commit to
- Study type: Observational
- Participants enrolled: 58
- From 11 Sept 2023 to the primary completion date, 11 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- incomplete acquisition of DWI images;
- presence of artifacts that do not allow quantitative analysis of DWI images;
- performance status 2 or more according to Zubrod.
Who the study is looking for
- age over 18 years;
- primary squamous cell carcinoma (SCC) of the hypopharynx, oropharynx, or oral cavity; confirmed by histology;
- a lesion visible on at least three consecutive DWI images, with a minimum diameter of 2 cm;
- specific written informed consent;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS National Cancer Institute "Regina Elena" Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.